MagnetisMM-5
Phase 3 Clinical Trial Evaluating The Safety and Effectiveness of Elranatamab Alone and Combined with Daratumumab Compared to the Combination of Daratumumab, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 944 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1170
- NCT Identifier
- NCT05020236
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.